Bristol Myers Squibb

News

Opdivo and Keytruda approved in new lung cancer uses

The FDA has approved Merck's Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), after green-lighting Bristol-Myers Squibb’s (BMS)

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

EU regulators reject new use for Opdivo, as Keytruda edges a...

Keytruda begins to win battle of the immunotherapies

News

BMS immunotherapy combo approved in new colorectal use

Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients with advanced colorectal cancer.

News